A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of PR006A in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)

Brief description of study

Evaluate the safety, tolerability, and immunogenicity of 3 dose levels of PR006A administered via sub-occipital injection into the cisterna magna and Quantify PGRN levels in blood and CSF. Please refer to section 2 of the attached protocol. Please refer to section 2 of the attached protocol.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

Updated on 09 Feb 2022. Study ID: 844811

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).